Wang Tian-Zuo, Liu Xin-Xin, Wang Si-Yu, Liu Yan, Pan Xin-Yang, Wang Jing-Jie, Nan Kai-Hui
State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou 325027, China.
National Clinical Research Center for Ocular Diseases, Wenzhou 325027, China.
Bioengineering (Basel). 2022 Dec 31;10(1):53. doi: 10.3390/bioengineering10010053.
Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.
干眼疾病(DED)是一种广泛存在且经常被报道的多因素眼病,不仅会引起眼部不适,还会损害角膜和结膜。目前,局部给药是干眼疾病最常见的治疗方式。由于存在多种生物屏障,滴入的药物通常在眼表作用时间短且渗透性差。为了解决这些问题,人们提出了几种先进的药物递送系统。本综述从其特点和优势方面讨论了用于治疗干眼疾病的药物新剂型。阐述了目前市场上已有的和正在进行临床研究的创新制剂。同时,也讨论了它们的不足之处。预计在不久的将来,先进药物递送系统的蓬勃发展将改善干眼疾病的治疗。